The purpose of this paper is to understand the association between antiepileptic drugs (AEDs), patient characteristics, changes in seizure pattern and emergent psychiatric disorder, i.e. psychosis or affective disorder. To this end we carried out a retrospective casenote study on 89 patients who developed psychiatric symptoms during treatment with topiramate, vigabatrin or tiagabine. The psychiatric problem was either an affective or a psychotic disorder (not including affective psychoses). It was discovered that 99% of the patients suffered from complex partial seizures with or without secondary generalization. More than half were on polytherapy with two or more other AEDs. Nearly two-thirds had a previous psychiatric history. There was a strong association between the type of previous psychiatric illness and the type of emerging psychiatric problem, both for psychoses and for affective disorders. Patients on vigabatrin had an earlier onset of epilepsy and more neurological abnormalities than those on topiramate. Those patients on lower doses had a shorter interval between the start of the AED therapy and the onset of the psychiatric problem. A seizure-free period was observed in more than half of the patients before they developed the psychiatric symptoms, and of these more were likely to develop a psychosis rather than an affective disorder. There seemed to be an association of suppression of right-sided seizures and the onset of the psychiatric problem. The conclusions drawn were that patients with a previous history of psychosis or affective disorder tended to develop the same psychiatric problem with new AEDs. Those with a seizure-free period before the onset of the psychiatric problem were more likely to develop a psychosis than an affective disorder.
INTRODUCTION
It is well known that antiepileptic drugs can lead to alterations of behaviour and mood. In the past barbiturates, and in particular polytherapy, have been associated with irritability and depression, which stand in contrast to the potential beneficial effects of some of these drugs. For example, carbamazepine and sodium valproate now have an established place in the management of bipolar affective disorders in psychiatric practice 1 . In contrast to affective disorders and irritability, psychoses have also been reported. Perhaps the most interesting reports originally came from the work of Landolt 2 when he observed the phenomenon of forced normalization in patients who were given the then newly prescribed ethosuximide. In these cases, suppression of seizures with ethosuximide led to a normalization of the previously abnormal EEG patterns, and a flowering of a psychosis. Tellenbach 3 gave the name 'alternative psychosis' to the clinical pattern without the underlying EEG evidence of normalization.
Psychoses have been observed with a number of other antiepileptics, but have recently been reported more frequently following the introduction of several new antiepileptic drugs in the last decade.
At the National Hospitals we have seen both affective disorders and psychoses as treatment-emergent effects of several of the newer agents, and have published data on some of these 4 . In this paper we exam-ine an extensive series of patients who presented with treatment-emergent psychiatric effects following the prescription of one of three new antiepileptic drugs, namely, vigabatrin, topiramate or tiagabine. We examine certain hypotheses, but particularly look at the effects on the mental state of the alteration of seizure pattern with the drugs.
MATERIALS AND METHODS
Patients in this study have been collected from several sources. Data on some patients have been previously published in a retrospective survey on vigabatrin. Most of those patients were seen and examined at the National Hospitals for Neurology and Neurosurgery, or the Chalfont Centre for Epilepsy, and they comprise the 'vigabatrin group'. There are five patients who were prescribed tiagabine and who went on to develop treatment emergent psychopathology, these all came from the Chalfont Centre for Epilepsy. These are referred to as the 'tiagabine group'. Finally, there are patients who have been reported as having developed similar effects following topiramate. These come from three centres (London, Birmingham and York) and are referred to as the 'topiramate group'. Data were collected on 94 patients who developed a psychiatric problem while being treated with one of the new antiepileptic drugs. Thus, the patients' notes were reviewed and detailed clinical information obtained. Where insufficient information was available the cases were no longer considered. Five patients were excluded for the following reasons: two because of a final diagnosis of pseudoseizures; one suffered from PTSD; one patient was intoxicated with phenytoin; and finally one case was complicated because several other drugs were being stopped and started simultaneously. So 89 patients were finally included in the study.
Following a review of the notes, patients were allocated into two main groups based upon the descriptive psychopathology. These were affective disorders and psychoses. Affective disorder ranged from severe dysthymia to affective psychosis, the latter always having mood-congruent delusions. A majority, however, had a major affective disorder. The designation 'affective disorder' was given only to patients who required psychiatric intervention or psychiatric assessment for their disorder.
The psychoses included patients with organic deliria, and inclusion criteria required delusions and/or hallucinations. The delusions would not be mood congruent. The psychoses could occur in clear consciousness, in which case they would be referred to as schizophrenia-like or paranoid, or with confusion, in which case they would be organic and deliria. The latter often, but not always, included post-ictal psychoses.
Following the collection of data the patient information was analysed on SPSS, version 7.5. Chi-square statistics were used for binomial data, or Fisher's exact test when the expected frequency in at least one cell was less than five. For comparison of means we performed t-tests, or Mann-Whitney tests if the data were not normally distributed.
RESULTS
Of the 89 patients, vigabatrin was prescribed to 50 (56%), topiramate to 34 (38%) and tiagabine to 5 (6%) ( Table 1) .
With respect to diagnosis, 40 patients (45%) suffered from an affective disorder, 30 (34%) with depression but also 8 (9%) with affective psychosis or hypomania (2) . In 49 cases (55%) there was a psychosis (excluding affective psychoses). The psychoses were (one case was unclear) 11 (12%) organic deliria, including the post-ictal states and 37 (42%) schizophrenia-like or paranoid states.
Of the patients, 54 (61%) were female, and the mean age was 34.7 years, with a range from 14 to 67 (SD 12.3). There were 28 (70%) women among the affective group and 26 (53%) in the psychosis group (chi-square = 2.6; P = 0.10).
The mean age of onset of the epilepsy (unknown in two cases) was 11.8 years (SD 12.2); however, it was significantly lower in the vigabatrin group than in the topiramate group (8 and 17 years respectively; t-test for independent samples: t = −3.5; two-tailed significance < 0.01; 95% CI −14.9 to −3.1). Symptomatic epilepsy (53, 61%) was more common than cryptogenic (34, 39%) (two unclear cases). There were less cryptogenic cases in the topiramate group (4 of 32, 13%) than in the vigabatrin group (28 of 50, 56%) (chi-square = 15.5, P < 0.001).
The most common seizure type (unknown in one) was complex partial seizures (70, 80%), followed by secondarily generalized seizures (37, 42%); 79 patients (90%) had complex partial seizures with or without secondary generalization. Primary generalized seizures were observed in 18 cases (20%), 10 (11%) of whom had both generalized and partial seizures and eight (9%) generalized seizures only. Twenty-eight psychotic patients (57%), but only nine affective patients (23%) suffered from secondarily generalized seizures (chi-square = 10.3; P < 0.01).
A neurological examination (done in 84 patients) was abnormal only in 12 (14%). There were significantly more abnormalities in the vigabatrin group (11, 22%) than in the topiramate group (1, 3%) (chi-square = 6.0; P < 0.05). Seventy-three patients had CT or MRI imaging carried out, and 36 (49%) had abnormal findings. In 28 cases (38%) there was a lateralized lesion, with 17 (23%) lesions in the right hemisphere being nonsignificantly more common than 11 (15%) in the left. Depressive patients had a higher proportion (18, 64%) of CT/MRI abnormalities than psychotic patients (18, 40%) (chi-square = 4.1; P < 0.05). Of 15 patients with a right-sided abnormality all showed either a period of seizure suppression or a decrease in seizure frequency prior to the onset of psychiatric problems (10 affective disorders and five psychoses), but only six (55%) of those with an abnormality in the left side (chi-square = 8.4; P < 0.01).
Eighty patients had an EEG which revealed abnormalities in 77 (96%), which were bilateral in 35 (44%), left sided in 20 and right sided in 22. Bilateral EEG abnormalities were nonsignificantly more common in the psychosis group (24, 52%) than in the depression group (11, 32%) (chi-square = 3.1; P = 0.08).
Only one patient was on monotherapy with the new drug. Aside from the new drug 40 (45%) were on monotherapy with another antiepileptic, mostly with carbamazepine (30, 34%), and 48 (55%) were on polytherapy with two or more other drugs. All in all carbamazepine was given to 62 patients (70%), phenytoin to 22 (25%) and sodium valproate to 13 (15%). Nine patients also took clobazam, eight lamotrigine, seven gabapentin and six each received clonazepam or primidone. Four were on phenobarbitone, four on vigabatrin (in addition to topiramate (three) or tiagabine (one) as the index drug), one on tiagabine (in the topiramate group) and one on diamox.
Vigabatrin was given at a mean dose of 2.7 g/day (SD 1.4), tiagabine with a mean of 29.6 mg/day (SD 22.2) and topiramate with 293 mg/day (SD 182). The distribution of doses with the latter drug suggested a bimodal distribution, with patients on either 400 mg/day or more (13, 38%) or on 300 mg or less (21, 62%) (see Fig. 1 ). There was no similar bimodal distribution on tiagabine or vigabatrin.
Arbitrarily taking more than 3 g of vigabatrin, over 40 mg of tiagabine and over 300 mg of topiramate as 'high doses', of 89 patients (the dose being unknown in one case) we distinguished 66 patients on a 'low dose' from 22 patients (25%) on a 'high dose'. There were eight (16%) patients on over 3 g vigabatrin, one patient (20%) on over 40 mg tiagabine and 13 (38%) patients on over 300 mg topiramate per day.
We suspect from clinical experience that the onset of the psychiatric problem is often associated with an increase in dose of an antiepileptic. However, due to a lack of information this could only be confirmed in 11 (12%) of our cases.
The time interval (unknown in two cases) between the prescription of one of the new antiepileptics and the onset of psychiatric symptoms was very variable, from immediate onset after the first dose to over 4 years, with a median of 8 weeks. The group of patients on a high dose (see above) had a much longer interval (median of 25 weeks) than the low dose group (median of 7 weeks), Mann-Whitney U = 349.5 and P < 0.001.
In 32 patients (36%), no evidence for any psychiatric history was found. Thirty (34%) had previously suffered from anxiety or depression, 17 (19%) from a psychotic episode and 10 (11%) from other disorders, e.g. behavioural problems or personality disorders.
There was a strong association between the psychiatric history and the present psychiatric problem: 15 of all psychotic patients (31%) but only two affective patients (5%) had a history of psychosis (chi-square = 9.3, P < 0.01). Similarly 20 of all affective patients (50%), but only 10 psychotic patients (20%) had had an affective disorder (chi-square = 8.6, P < 0.01).
Just before the onset of the psychiatric symptoms, five different patterns of seizures occurred (unknown in six): in 22 patients (27%) the seizures were completely suppressed, 20 patients (24%) had a seizurefree interval followed by a cluster of seizures (postictal); there was a decreased frequency, but not freedom from attacks in 22 (27%), no change in 16 (19%) and more seizures in three (4%) patients.
With regards to completely seizure-free patients, there was a higher proportion in the psychosis group (15, 34%) than in the depression group (7, 18%) (not significant, chi-square = 2.8; P = 0.10). There was a difference, however, between the group on vigabatrin and those on topiramate ( Table 2 ). The group on topiramate had more affective patients with complete resolution of seizures. There were more patients with no change in seizure frequency or even more seizures in the topiramate group (10, 33%) than in the vigabatrin group (7, 16%); however, this was not significant (chi-square = 2.4; P = 0.12).
There was, however, a significant relationship with psychiatric diagnosis. Following the two seizure patterns with a seizure-free period, i.e. complete suppression of seizures or suppression of seizures followed by clusters, there were significantly more psychoses (27, 61%) than depressions (15, 38%) (chi-square = 4.3; P < 0.05). Again there were differences between topiramate and vigabatrin, the latter showing more psychosis than depression.
We then analysed the difference between patients who became seizure-free or had a reduced frequency of attacks, but no differences emerged (Table 3) .
DISCUSSION
In this paper we have analysed the data from patients who have developed either an affective disorder or a psychosis as a treatment emergent effect of one of three new antiepileptic agents. There are always problems with retrospective data, not the least being the amount of missing data. Further, clinical descriptions of, for example, the phenomenology of the mental state, are often less than adequate. We have been fortunate to have almost complete data on most of the variables we have been examining, and generally the quality of the clinical material available to us was satisfactory. At the outset patients were excluded where we did not feel there was sufficient information to include them in our data set.
Obviously a prospective study is more favourable, but these cases are not so common in general neurological practice. However, these psychiatric problems are frequently encountered by specialists but are often difficult to examine at the time of the acute psychosis, either because they often occur when the patient is in the community or the patient is seen by psychiatrists rather than neurologists. All of the patients in this series have been examined by the physicians involved in reporting these cases, increasing the quality of the data obtained.
We believe this is the largest series of patients reported who have developed such symptoms following the onset of antiepileptic drugs, and there is some justification for including patients from three different series. However, we have shown some subtle differences between the drugs which bear further discussion.
With regards to the overall group, we have uncovered some differences between seizure patterns in patients who develop affective as opposed to psychotic disorders. The psychotic group appear to have more secondarily generalized seizures, and more bilateral EEG abnormalities. This is in keeping with the suggestion that psychotic states in epilepsy may be associated with more widespread cerebral abnormalities and a propensity of seizures to spread through limbic structures. Further, the relative under-reporting of secondarily generalized seizures in the affective disorder group is similar to the findings of some others who have examined links between affective disorder and epilepsy. Flor-Henry 5 , for example, in his paper on patients worked up for temporal lobectomy, reported that affective psychoses were correlated with 'major convulsive epilepsy' infrequently manifested.
This extended sample reveals further interesting relationships between the past history of psychiatric problems and the pattern of the development of the emergent psychiatric syndrome. Approximately a third of our sample had no evidence of a past psychiatric history, although it is possible that there was some under-reporting here. However, the fact that twothirds of patients had a clear past history emphasises the importance of a psychiatric anamnesis before starting patients on these new drugs. Further, the fact that people with a past history of depression tend to get an affective picture, and those who have a past history of psychosis develop psychotic syndromes' raises interesting questions as to the effect of the drugs on the central nervous system and how that leads to the emergent psychiatric picture. The drugs essentially appear to be driving the underlying constitutional liability of these patients, the direction in which they are driven being given by the past psychiatric profile.
Although not significant it may be relevant that psychiatric problems were seen more commonly following a right hemisphere abnormality, since other data suggest that when affective disorder or psychosis emerge, not in a treatment setting but interictally, there is a bias towards left hemisphere involvement 6 . These data seem to fit with some recent studies 7 of the results of temporal lobe surgery, where again more severe psychiatric problems appear to emerge following right hemisphere resection. These data suggest that patients with complex partial seizures that secondarily generalize who have right hemisphere lesions may be the more susceptible to develop psychosis if they become seizure-free with these treatments.
Most patients were on polytherapy, and the variety of drugs, as expected, was wide. Interactions between different drugs, leading to the emergent psychiatric syndrome cannot be speculated on, but it is possible that these psychiatric syndromes do not occur with the same frequency when patients are treated with monotherapy. This certainly seems to be the case with the monotherapy trials so far published in which psychiatric problems are less frequently reported.
We have uncovered some interesting differences between the group on vigabatrin and those on topiramate. It is possible that these relate to selection factors. However, the vigabatrin group appeared more likely to have an early onset of epilepsy, and an abnormal neurological examination. This may reflect that they had more severe epilepsy, although unexplained is the fact that more of them also reported as having a cryptogenic aetiology. The latter may well be an artefact of the difficulty of collecting these kind of data.
Proportionately more of the topiramate group were receiving higher doses of the drug than for the other drugs. When compared with vigabatrin, there was a suggestion of more patients on topiramate with no change, or an increase, in seizures. These data suggest that some emergent psychiatric problems with topiramate may be more common following escalation of dose. This may be due to patients being unresponsive to the drug, and the dose therefore being increased leading to an intoxication with topiramate. This is further supported by the observation that patients taking a 'high dose' of drugs had a longer time interval to the onset of psychiatric problems.
We have looked at patterns of psychopathology that emerge with alteration of seizures. It appears to be the case that freedom from seizures, as opposed to merely reducing seizure frequency, is most relevant for the development of psychosis supporting the original observations of Landolt 2 and Tellenbach 3 . Interestingly, there may well be a difference between topiramate and vigabatrin again, the topiramate group having more affective disorder with complete suppression of seizures. Whether this reflects subtle biochemical differences between the drugs is unclear. These data tend to suggest that the Landolt phenomenon, which is known from other studies 8 to be associated with a variety of clinical presentations, is more likely to be interlinked with a productive psychosis than an affective disorder, but that the final expression of that may be dependent on the predisposition of the patient (see above) and the actual drug prescribed.
In conclusion, we have studied the emergence of psychopathology in patients who have been started on a new antiepileptic drug. Both affective disorders and psychoses are seen, the latter seem more interlinked with complete suppression of seizures. There may be subtle differences between vigabatrin and topiramate in their biochemical effects which lead to differing clinical profiles, which we have explored here.
